SUNNYVALE, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today positive results from three multicenter first-in-man studies of NovolimusTM and MyolimusTM eluting coronary stent systems with durable and bioabsorbable polymers. Findings were presented at the 21st Annual Transcatheter Cardiovascular Therapeutics (TCT 2009) scientific symposium.
